fsgs
DESCRIPTION
FSGS by Dr Amit AgrawalTRANSCRIPT
![Page 1: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/1.jpg)
Focal Segmental Glomerulo-Sclerosis
Dr. Amit Agrawal
![Page 2: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/2.jpg)
Learning objectives
• Filtration barrier• Pathophysiology of FSGS• Genetics of FSGS• Management of FSGS• Recurrence of FSGS in Graft• Management of Recurrence
![Page 3: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/3.jpg)
Glomerular Filtration Barrier
![Page 4: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/4.jpg)
Progressive changes
(1) Foot process effacement; (2) Podocyte apoptosis/loss and exposed
glomerular basement membrane; (3) Filtration of non-specific plasma proteins;(4) Capillary expansion;(5) Misdirected filtration at points of synechiae;(6) Formation of synechiae; (7) Mesangial matrix proliferation
![Page 5: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/5.jpg)
![Page 6: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/6.jpg)
Causes of Focal Segmental Glomerulosclerosis
Primary (idiopathic) form:• Specific cause unknown• Mediated by circulating permeability factorsSecondary forms:Familial or genetic:Mutations in specific podocyte genes
![Page 7: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/7.jpg)
Virus-associated:• Human immunodeficiency virus type 1• Parvovirus B19 • Simian virus 40• Cytomegalovirus• Epstein–Barr virus
![Page 8: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/8.jpg)
Drug-induced :• Heroin• Interferon's Alfa, beta, and gamma • Lithium• Pamidronate • Sirolimus• Calcineurin-inhibitor nephrotoxicity • Anabolic steroids
![Page 9: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/9.jpg)
Adaptive
Conditions with reduced renal mass:• Oligomeganephronia• Very low birth weight• Unilateral renal agenesis • Renal dysplasia• Reflux nephropathy• Sequela to cortical necrosis• Surgical renal ablation • Renal allograft • Aging kidney• Any advanced renal disease with reduced functioning nephrons
![Page 10: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/10.jpg)
Conditions with initially normal renal mass
• Systemic hypertension,• Acute or chronic vaso-occlusive processes (atheroembolization, thrombotic
microangiopathy, renal-artery stenosis)• Elevated body-mass index (obesity)• Increased lean body mass [bodybuilding]• Cyanotic congenital heart disease • Sickle cell anaemia
![Page 11: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/11.jpg)
![Page 12: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/12.jpg)
Treatment
![Page 13: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/13.jpg)
Recurrence of FSGS after renal transplantation
• Primary type FSGS recurs in about 30% of grafts after transplantation. The time of diagnosis averages about two wk
after surgery in children and 7.5 months in adults
![Page 14: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/14.jpg)
Risk factors for recurrence of FSGS
• Childhood onset (onset under the age of 6yr is associated with a recurrence rate of 50–80%)
• Age <15 yr, rapid progression (within three yr) from diagnosis to ESRD
• Diffuse mesangial hypercellularity in the native kidney
• Recurrence of FSGS in a previous allograft• Collapsing FSGS
![Page 15: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/15.jpg)
• Two clinical presentations of FSGS after transplantationEarly recurrenceLate recurrence
![Page 16: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/16.jpg)
Pathogenesis
• Podocyte injury could be caused by circulating factor secreted by an abnormal clone of T cells
• The permeability factor may induce redistribution and loss of nephrin as well as reduced expression of podocin
![Page 17: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/17.jpg)
Histo-Pathology• Podocyte foot process effacement is considered the
pathognomonic feature of the early stage of recurrence of FSGS
• Podocyte detachment from the GBM and loss of podocytes
• Podocytes hyperplasia- pathological factor in disease progression• Transdifferentiation, • Dysregulation,• Epithelial mesenchymal transformation develop in
hyperplastic epithelial cells in FSGS
![Page 18: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/18.jpg)
![Page 19: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/19.jpg)
![Page 20: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/20.jpg)
Treatment
• Plasma exchanges only• High-dose oral or intravenous cyclosporine A• Plasma exchange plus cyclophosphamide• Plasma exchange plus CyA• Plasma exchange plus CyA plus cyclophosphamide
![Page 21: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/21.jpg)
Plasma exchange
• Replacement of 1.5 plasma volumes (50–60 ml/kg) by 5% albumin.
• Least three plasma exchanges per week and a progressive tapering down plus
• 10–14 days of IV CyA (trough level 200–400 ng/ml) followed by
• oral CyA with C2 levels of 1200–1400 ng/ml
![Page 22: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/22.jpg)
• Very intensified plasma exchange (daily for 10 days followed by 3 per week over 2 weeks)
• Together with oral CyA (C2 1600– 2000 ng/ml)
![Page 23: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/23.jpg)
Plasma exchange and cyclophosphamide
• Plasma exchanges, which was performed 6 –10 times over 15–24 days, plus oral cyclophosphamide
• Plasmapheresis performed 10 times over 2 weeks followed by one session per week for 2 months, combined with cyclophosphamide
![Page 24: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/24.jpg)
Rituximab• Weekly infusions of 375 mg/ m2of rituximab
for 2 – 4 weeks.Adalimumabdirected against tumor necrosis factor α (TNF- α)RosiglitazonePeroxisome proliferator-activated receptor-γ
agonist
![Page 25: Fsgs](https://reader035.vdocuments.net/reader035/viewer/2022062513/555f1fd4d8b42a93658b4cbc/html5/thumbnails/25.jpg)
• Galactose: Block the binding site or change the
configuration of the free soluble factor, preventing it from binding to the podocytes
• Podocyte stem cells therapy